- Home
- CIK vs CGTX Comparison
CIK vs CGTX Comparison
Compare CIK & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIK | CGTX |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CIK | CGTX |
|---|---|---|
| Price | $2.81 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 115.4K | ★ 971.4K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $0.22 |
| 52 Week High | $3.19 | $3.83 |
Technical Indicators
Market Signals| Indicator | CIK | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 30.45 |
| Support Level | $2.79 | $1.08 |
| Resistance Level | $2.84 | $1.18 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 29.41 | 3.19 |
Price Performance
Historical ComparisonAbout CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.